$OPK as a biotechnology and pharmaceutical company, after today's acquisition, will branch into clinical laboratory services. Opko has previously been focused on developing products for that industry, such as a test to detect Alzeimer’s disease for which it granted Laboratory Corp. of America Holdings an exclusive license to implement.
Market Data 
Markets 
AI
